All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

desipramine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
substances of the imipramine group	812	50-47-5

Description:

Molecule

Description

Molfile Inchi Smiles Synonyms: desipramine demethylimipramine desimipramine desipramin desmethylimipramine methylaminopropyliminodibenzyl monodemethylimipramine norimipramine desipramine hydrochloride desipramine HCl

A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors. Molecular weight: 266.39 Formula: C18H22N2 CLOGP: 4.47 LIPINSKI: 0 HAC: 2 HDO: 1 TPSA: 15.27 ALOGS: -3.83 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

Dose	Unit	Route
0.10	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	2 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	16.09 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	82.50 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	15 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	11 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.16 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	22 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Nov. 20, 1964	FDA	SANOFI AVENTIS US

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Completed suicide	141.05	31.73	66	1116	131823	50472119
Hyperkeratosis	114.77	31.73	26	1156	5009	50598933
Cardiac murmur	95.09	31.73	26	1156	10758	50593184
Angina pectoris	72.38	31.73	26	1156	26162	50577780
Dyspnoea exertional	61.78	31.73	28	1154	51205	50552737
Immune thrombocytopenia	57.98	31.73	17	1165	9000	50594942
Intestinal obstruction	50.37	31.73	20	1162	26363	50577579
Urinary retention	47.04	31.73	19	1163	26171	50577771
Ileus	43.64	31.73	15	1167	13214	50590728
Toxicity to various agents	36.75	31.73	34	1148	212465	50391477
Osteoarthritis	34.80	31.73	21	1161	68585	50535357

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Completed suicide	67.73	33.67	31	423	90215	29483858

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Completed suicide	193.06	29.05	98	1474	224316	64272844
Hyperkeratosis	76.50	29.05	20	1552	6661	64490499
Cardiac murmur	65.65	29.05	20	1552	11543	64485617
Toxicity to various agents	49.49	29.05	52	1520	363461	64133699
Immune thrombocytopenia	48.65	29.05	17	1555	15049	64482111
Intestinal obstruction	43.37	29.05	20	1552	36266	64460894
Angina pectoris	42.18	29.05	21	1551	45060	64452100
Dyspnoea exertional	40.16	29.05	24	1548	73706	64423454
Osteoarthritis	35.48	29.05	21	1551	63315	64433845
Drug intolerance	35.02	29.05	32	1540	187960	64309200
Ileus	34.95	29.05	15	1557	22951	64474209
Urinary retention	34.79	29.05	19	1553	49182	64447978
Therapy non-responder	29.64	29.05	19	1553	65880	64431280

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N06AA01	NERVOUS SYSTEM PSYCHOANALEPTICS ANTIDEPRESSANTS Non-selective monoamine reuptake inhibitors
CHEBI has role	CHEBI:88188	allergenic drug
MeSH PA	D018663	Adrenergic Agents
MeSH PA	D018759	Adrenergic Uptake Inhibitors
MeSH PA	D000928	Antidepressive Agents
MeSH PA	D000929	Antidepressive Agents, Tricyclic
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D049990	Membrane Transport Modulators
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D014179	Neurotransmitter Uptake Inhibitors
MeSH PA	D011619	Psychotropic Drugs
FDA EPC	N0000175752	Tricyclic Antidepressant
CHEBI has role	CHEBI:35469	antidepressants
CHEBI has role	CHEBI:35640	adrenergic uptake inhibitors
CHEBI has role	CHEBI:37890	alpha-adrenergic receptor blockaders
CHEBI has role	CHEBI:37955	H1 receptor antagonists
CHEBI has role	CHEBI:48873	acetylcholine receptor antagonist
CHEBI has role	CHEBI:50949	SSRI
CHEBI has role	CHEBI:76779	post-proline endopeptidase inhibitors
CHEBI has role	CHEBI:76811	sphingomyelin cholinephosphohydrolase inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Depressive disorder	indication	35489007
Cataplexy	off-label use	46263000
Anxiety	off-label use	48694002
Bulimia nervosa	off-label use	78004001
Neuropathic pain	off-label use	247398009
Chronic idiopathic urticaria	off-label use	302162004
Panic disorder	off-label use	371631005	DOID:594
Attention deficit hyperactivity disorder	off-label use	406506008
Depressive Disorder following Traumatic Brain Injury	off-label use
Suicidal thoughts	contraindication	6471006
Alcoholism	contraindication	7200002
Bipolar disorder	contraindication	13746004	DOID:3312
Lowered convulsive threshold	contraindication	19260006
Glaucoma	contraindication	23986001	DOID:1686
Torsades de pointes	contraindication	31722008
Hyperthyroidism	contraindication	34486009	DOID:7998
Conduction disorder of the heart	contraindication	44808001
Schizophrenia	contraindication	58214004	DOID:5419
Epilepsy	contraindication	84757009	DOID:1826
Kidney disease	contraindication	90708001	DOID:557
Prolonged QT interval	contraindication	111975006
Seizure disorder	contraindication	128613002
Cerebrovascular accident	contraindication	230690007
Disease of liver	contraindication	235856003	DOID:409
Benign prostatic hyperplasia	contraindication	266569009
Retention of urine	contraindication	267064002
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Myocardial infarction in recovery phase	contraindication	418044006
Congenital long QT syndrome	contraindication	442917000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.83	Basic
pKa2	5.01	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN	INHIBITOR	Kd	9.08		WOMBAT-PK	CHEMBL
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		EC50	6.50		WOMBAT-PK
Alpha-1A adrenergic receptor	GPCR	P35348	ADA1A_HUMAN		Ki	7		WOMBAT-PK
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	6.80		WOMBAT-PK
D(1A) dopamine receptor	GPCR	P21728	DRD1_HUMAN		Ki	5.26		PDSP
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN		Ki	5.63		PDSP
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	5.86		PDSP
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		Ki	5.86		WOMBAT-PK
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		Kd	7.76		WOMBAT-PK
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	5.19		PDSP
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN					WOMBAT-PK
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN		Ki	7.12		WOMBAT-PK
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN		Ki	6.76		WOMBAT-PK
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN		Ki	6.27		WOMBAT-PK
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN		Ki	6.68		WOMBAT-PK
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN		Ki	6.80		WOMBAT-PK
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN		Ki	6.84		WOMBAT-PK
5-hydroxytryptamine receptor 1B	GPCR	P28222	5HT1B_HUMAN		Ki	6.98		PDSP
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	9.31		CHEMBL
Voltage-dependent calcium channel gamma-1 subunit	Ion channel	Q06432	CCG1_HUMAN					WOMBAT-PK
Solute carrier family 22 member 1	Transporter	O15245	S22A1_HUMAN		IC50	4.25		CHEMBL
Sodium channel alpha subunits; brain (Types I, II, III)	Ion channel	P35498 Q99250 Q9NY46	SCN1A_HUMAN SCN2A_HUMAN SCN3A_HUMAN		IC50	5.62		CHEMBL
Equilibrative nucleoside transporter 4	Transporter	Q7RTT9	S29A4_HUMAN	INHIBITOR	Ki	4.49		IUPHAR
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		EC50	6.50		WOMBAT-PK
Alpha-1A adrenergic receptor	GPCR		ADA1A_RAT		IC50	9.60		CHEMBL
Sodium-dependent serotonin transporter	Transporter		SC6A4_RAT		Ki	6.79		CHEMBL
Sodium-dependent dopamine transporter	Transporter		SC6A3_RAT		Ki	5.19		CHEMBL
Transporter	Transporter		Q9WTR4_RAT		Ki	9.19		CHEMBL
Sodium-dependent noradrenaline transporter	Transporter		SC6A2_MOUSE		IC50	5.80		CHEMBL
Sodium-dependent serotonin transporter	Transporter		SC6A4_MOUSE		IC50	5.03		CHEMBL
Histamine H1 receptor	GPCR		HRH1_RAT		IC50	9.10		CHEMBL
Transporter	Transporter		Q63380_RAT		Ki	9.11		CHEMBL
Serotonin (5-HT) receptor	GPCR		5HT2C_RAT 5HT2A_RAT 5HT1A_RAT 5HT1B_RAT 5HT1D_RAT 5HT1F_RAT 5HT2B_RAT 5HT6R_RAT 5HT7R_RAT 5HT5A_RAT 5HT5B_RAT 5HT3A_RAT 5HT4R_RAT 5HT3B_RAT		IC50	6.46		CHEMBL
G protein-activated inward rectifier potassium channel 4	Ion channel		KCNJ5_MOUSE	BLOCKER	IC50	4.30		IUPHAR
G protein-activated inward rectifier potassium channel 2	Ion channel		KCNJ6_MOUSE	BLOCKER	IC50	4.40		IUPHAR

External reference:

ID	Source
4019708	VUID
N0000147800	NUI
D00812	KEGG_DRUG
58-28-6	SECONDARY_CAS_RN
203174	RXNORM
4018608	VANDF
4019708	VANDF
C0011685	UMLSCUI
CHEBI:47781	CHEBI
DSM	PDB_CHEM_ID
CHEMBL72	ChEMBL_ID
DB01151	DRUGBANK_ID
CHEMBL1696	ChEMBL_ID
D003891	MESH_DESCRIPTOR_UI
2995	PUBCHEM_CID
2399	IUPHAR_LIGAND_ID
1500	INN_ID
TG537D343B	UNII
1064	MMSL
4547	MMSL
d00145	MMSL
001503	NDDF
004602	NDDF
26120001	SNOMEDCT_US
33378002	SNOMEDCT_US
372705002	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Desipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-8218	TABLET, FILM COATED	10 mg	ORAL	ANDA	20 sections
Desipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-8972	TABLET, FILM COATED	25 mg	ORAL	ANDA	20 sections
Desipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-8973	TABLET, FILM COATED	50 mg	ORAL	ANDA	20 sections
Desipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-8974	TABLET, FILM COATED	75 mg	ORAL	ANDA	20 sections
Desipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-8975	TABLET, FILM COATED	100 mg	ORAL	ANDA	20 sections
Desipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-8976	TABLET, FILM COATED	150 mg	ORAL	ANDA	20 sections
DESIPRAMINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	16590-586	TABLET, FILM COATED	100 mg	ORAL	ANDA	20 sections
DESIPRAMINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	16590-830	TABLET, FILM COATED	10 mg	ORAL	ANDA	20 sections
Desipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	21695-428	TABLET, FILM COATED	25 mg	ORAL	ANDA	20 sections
Desipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	21695-845	TABLET	10 mg	ORAL	ANDA	15 sections
DESIPRAMINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	23155-578	TABLET	10 mg	ORAL	ANDA	13 sections
DESIPRAMINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	23155-579	TABLET	25 mg	ORAL	ANDA	13 sections
DESIPRAMINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	23155-580	TABLET	50 mg	ORAL	ANDA	13 sections
DESIPRAMINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	23155-581	TABLET	75 mg	ORAL	ANDA	13 sections
DESIPRAMINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	23155-582	TABLET	100 mg	ORAL	ANDA	13 sections
DESIPRAMINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	23155-583	TABLET	150 mg	ORAL	ANDA	13 sections
Desipramine Hydrochloride	Human Prescription Drug Label	1	24724-067	TABLET	10 mg	ORAL	ANDA	17 sections
Desipramine Hydrochloride	Human Prescription Drug Label	1	24724-068	TABLET	25 mg	ORAL	ANDA	17 sections
Desipramine Hydrochloride	Human Prescription Drug Label	1	24724-069	TABLET	50 mg	ORAL	ANDA	17 sections
Desipramine Hydrochloride	Human Prescription Drug Label	1	24724-070	TABLET	75 mg	ORAL	ANDA	17 sections
Desipramine Hydrochloride	Human Prescription Drug Label	1	24724-071	TABLET	100 mg	ORAL	ANDA	17 sections
Desipramine Hydrochloride	Human Prescription Drug Label	1	24724-072	TABLET	150 mg	ORAL	ANDA	17 sections
Norpramin	HUMAN PRESCRIPTION DRUG LABEL	1	30698-007	TABLET, SUGAR COATED	10 mg	ORAL	NDA	21 sections
Norpramin	HUMAN PRESCRIPTION DRUG LABEL	1	30698-011	TABLET, SUGAR COATED	25 mg	ORAL	NDA	21 sections
Norpramin	HUMAN PRESCRIPTION DRUG LABEL	1	30698-015	TABLET, SUGAR COATED	50 mg	ORAL	NDA	21 sections
Norpramin	HUMAN PRESCRIPTION DRUG LABEL	1	30698-019	TABLET, SUGAR COATED	75 mg	ORAL	NDA	21 sections
Norpramin	HUMAN PRESCRIPTION DRUG LABEL	1	30698-020	TABLET, SUGAR COATED	100 mg	ORAL	NDA	21 sections
Norpramin	HUMAN PRESCRIPTION DRUG LABEL	1	30698-021	TABLET, SUGAR COATED	150 mg	ORAL	NDA	21 sections
Desipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	45963-341	TABLET, FILM COATED	10 mg	ORAL	ANDA	16 sections
Desipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	45963-342	TABLET, FILM COATED	25 mg	ORAL	ANDA	16 sections